# OptimizeRx Corp: financial statements, quarterly

OPRX · Nasdaq · CIK 1448431 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oprx.md) · [Financials](/companies/oprx/financials.md) · [Filings](/companies/oprx/filings.md) · [Insiders](/companies/oprx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/oprx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [16.3](/filings/0001213900-24-098319.md) | [28.4 d](/filings/0001213900-25-025576.md) | [19.7](/filings/0001448431-25-000005.md) | [18.8](/filings/0001448431-25-000012.md) | [21.3](/filings/0001448431-25-000020.md) | [32.3 d](/filings/0001448431-26-000005.md) | [21.9](/filings/0001448431-26-000011.md) | [29.2](/filings/0001448431-26-000016.md) | [26.1](/filings/0001448431-25-000020.md) | [32.2 d](/filings/0001448431-26-000005.md) | [19.8](/filings/0001448431-26-000011.md) | [20.5](/filings/0001448431-26-000016.md) |
| Cost of revenue | $m | [6.5](/filings/0001213900-24-098319.md) | [10.5 d](/filings/0001213900-25-025576.md) | [7.5](/filings/0001448431-25-000005.md) | [7.1](/filings/0001448431-25-000012.md) | [7.9](/filings/0001448431-25-000020.md) | [10.3 d](/filings/0001448431-26-000005.md) | [8.6](/filings/0001448431-26-000011.md) | [10.6](/filings/0001448431-26-000016.md) | [8.6](/filings/0001448431-25-000020.md) | [8.1 d](/filings/0001448431-26-000005.md) | [4.9](/filings/0001448431-26-000011.md) | [4.8](/filings/0001448431-26-000016.md) |
| Gross profit | $m | [9.8](/filings/0001213900-24-098319.md) | [17.8 d](/filings/0001213900-25-025576.md) | [12.2](/filings/0001448431-25-000005.md) | [11.7](/filings/0001448431-25-000012.md) | [13.4](/filings/0001448431-25-000020.md) | [22.0 d](/filings/0001448431-26-000005.md) | [13.3](/filings/0001448431-25-000005.md) | [18.6](/filings/0001448431-25-000012.md) | [17.5](/filings/0001448431-25-000020.md) | [24.1 d](/filings/0001448431-26-000005.md) | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | [3.3](/filings/0001448431-26-000011.md) | [3.1](/filings/0001448431-26-000016.md) | not reported | not reported | [3.4](/filings/0001448431-26-000011.md) | [3.3](/filings/0001448431-26-000016.md) |
| Selling, general and administrative | $m | [12.9](/filings/0001213900-23-086885.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(3.6)](/filings/0001213900-24-098319.md) | [(10.9) d](/filings/0001213900-25-025576.md) | [(5.0)](/filings/0001448431-25-000005.md) | [(3.7)](/filings/0001448431-25-000012.md) | [(8.6)](/filings/0001448431-25-000020.md) | [3.6 d](/filings/0001448431-26-000005.md) | [(2.1)](/filings/0001448431-26-000011.md) | [3.2](/filings/0001448431-26-000016.md) | [2.1](/filings/0001448431-25-000020.md) | [8.6 d](/filings/0001448431-26-000005.md) | [0.4](/filings/0001448431-26-000011.md) | [(0.1)](/filings/0001448431-26-000016.md) |
| Interest expense | $m | not reported | not reported | [1.5](/filings/0001213900-24-043749.md) | [1.5](/filings/0001448431-25-000012.md) | [1.5](/filings/0001448431-25-000020.md) | [1.6 d](/filings/0001448431-26-000005.md) | [1.3](/filings/0001448431-26-000011.md) | [1.6](/filings/0001448431-26-000016.md) | [1.2](/filings/0001448431-25-000020.md) | [1.2 d](/filings/0001448431-26-000005.md) | [1.2](/filings/0001448431-26-000011.md) | [1.1](/filings/0001448431-26-000016.md) |
| Income tax | $m | not reported | not reported | [0.3](/filings/0001448431-25-000005.md) | [(1.1)](/filings/0001448431-25-000012.md) | [(0.8)](/filings/0001448431-25-000020.md) | [2.3 d](/filings/0001448431-26-000005.md) | [(1.1)](/filings/0001448431-26-000011.md) | [0.2](/filings/0001448431-26-000016.md) | [0.3](/filings/0001448431-25-000020.md) | [2.5 d](/filings/0001448431-26-000005.md) | [(0.1)](/filings/0001448431-26-000011.md) | [(0.4)](/filings/0001448431-26-000016.md) |
| Net income | $m | [(2.9)](/filings/0001213900-24-098319.md) | [(4.1) d](/filings/0001213900-25-025576.md) | [(6.9)](/filings/0001448431-25-000020.md) | [(4.0)](/filings/0001448431-25-000020.md) | [(9.1)](/filings/0001448431-25-000020.md) | [(0.1) d](/filings/0001448431-26-000005.md) | [(2.2)](/filings/0001448431-26-000016.md) | [1.5](/filings/0001448431-26-000016.md) | [0.8](/filings/0001448431-25-000020.md) | [5.0 d](/filings/0001448431-26-000005.md) | [(0.5)](/filings/0001448431-26-000016.md) | [(0.7)](/filings/0001448431-26-000016.md) |
| Diluted EPS | $ per share | [(0.17)](/filings/0001213900-24-098319.md) | not reported | [(0.38)](/filings/0001448431-25-000005.md) | [(0.22)](/filings/0001448431-25-000012.md) | [(0.50)](/filings/0001448431-25-000020.md) | not reported | [(0.12)](/filings/0001448431-26-000011.md) | [0.08](/filings/0001448431-26-000016.md) | [0.04](/filings/0001448431-25-000020.md) | not reported | [(0.03)](/filings/0001448431-26-000011.md) | [(0.04)](/filings/0001448431-26-000016.md) |
| Basic EPS | $ per share | [(0.17)](/filings/0001213900-24-098319.md) | not reported | [(0.38)](/filings/0001448431-25-000005.md) | [(0.22)](/filings/0001448431-25-000012.md) | [(0.50)](/filings/0001448431-25-000020.md) | not reported | [(0.12)](/filings/0001448431-26-000011.md) | [0.08](/filings/0001448431-26-000016.md) | [0.04](/filings/0001448431-25-000020.md) | not reported | [(0.03)](/filings/0001448431-26-000011.md) | [(0.04)](/filings/0001448431-26-000016.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [13.9](/filings/0001213900-25-025576.md) | not reported | not reported | [16.1](/filings/0001213900-24-098319.md) | [13.4](/filings/0001448431-26-000005.md) | [16.6](/filings/0001448431-25-000005.md) | [16.6](/filings/0001448431-25-000012.md) | [19.5](/filings/0001448431-25-000020.md) | [23.4](/filings/0001448431-26-000016.md) | [20.2](/filings/0001448431-26-000011.md) | [24.1](/filings/0001448431-26-000016.md) |
| Current assets | $m | [87.4](/filings/0001213900-23-086885.md) | [54.3](/filings/0001213900-25-025576.md) | [48.4](/filings/0001213900-24-043749.md) | [46.0](/filings/0001213900-24-069700.md) | [46.9](/filings/0001213900-24-098319.md) | [54.0](/filings/0001448431-26-000005.md) | [51.7](/filings/0001448431-25-000005.md) | [54.1](/filings/0001448431-25-000012.md) | [56.3](/filings/0001448431-25-000020.md) | [64.7](/filings/0001448431-26-000016.md) | [56.2](/filings/0001448431-26-000011.md) | [54.1](/filings/0001448431-26-000016.md) |
| Total assets | $m | [124](/filings/0001213900-23-086885.md) | [183](/filings/0001213900-25-025576.md) | [176](/filings/0001213900-24-043749.md) | [173](/filings/0001213900-24-069700.md) | [165](/filings/0001213900-24-098319.md) | [171](/filings/0001448431-26-000005.md) | [168](/filings/0001448431-25-000005.md) | [169](/filings/0001448431-25-000012.md) | [170](/filings/0001448431-25-000020.md) | [177](/filings/0001448431-26-000016.md) | [167](/filings/0001448431-26-000011.md) | [164](/filings/0001448431-26-000016.md) |
| Current liabilities | $m | [7.7](/filings/0001213900-23-086885.md) | [17.9](/filings/0001213900-25-025576.md) | [16.8](/filings/0001213900-24-043749.md) | [15.0](/filings/0001213900-24-069700.md) | [14.5](/filings/0001213900-24-098319.md) | [18.7](/filings/0001448431-26-000005.md) | [18.4](/filings/0001448431-25-000005.md) | [21.1](/filings/0001448431-25-000012.md) | [18.5](/filings/0001448431-25-000020.md) | [21.3](/filings/0001448431-26-000016.md) | [10.5](/filings/0001448431-26-000011.md) | [9.7](/filings/0001448431-26-000016.md) |
| Total liabilities | $m | [7.8](/filings/0001213900-23-086885.md) | [56.8](/filings/0001213900-25-025576.md) | [53.8](/filings/0001213900-24-043749.md) | [51.9](/filings/0001213900-24-069700.md) | [50.7](/filings/0001213900-24-098319.md) | [54.2](/filings/0001448431-26-000005.md) | [51.5](/filings/0001448431-25-000005.md) | [50.0](/filings/0001448431-25-000012.md) | [48.1](/filings/0001448431-25-000020.md) | [48.6](/filings/0001448431-26-000016.md) | [37.7](/filings/0001448431-26-000011.md) | [33.2](/filings/0001448431-26-000016.md) |
| Long-term debt | $m | [0.0](/filings/0001213900-23-086885.md) | [34.2](/filings/0001213900-25-025576.md) | [32.4](/filings/0001213900-24-043749.md) | [32.3](/filings/0001213900-24-069700.md) | [33.3](/filings/0001213900-24-098319.md) | [30.8](/filings/0001448431-26-000005.md) | [29.2](/filings/0001448431-25-000005.md) | [25.1](/filings/0001448431-25-000012.md) | [24.8](/filings/0001448431-25-000020.md) | [21.4](/filings/0001448431-26-000016.md) | [21.3](/filings/0001448431-26-000011.md) | [17.8](/filings/0001448431-26-000016.md) |
| Current portion of debt | $m | not reported | [2.0](/filings/0001213900-25-025576.md) | [3.5](/filings/0001213900-24-043749.md) | [3.3](/filings/0001213900-24-069700.md) | [2.0](/filings/0001213900-24-098319.md) | [2.0](/filings/0001448431-26-000005.md) | [3.3](/filings/0001448431-25-000005.md) | [3.3](/filings/0001448431-25-000012.md) | [3.3](/filings/0001448431-25-000020.md) | [4.3](/filings/0001448431-26-000016.md) | [2.0](/filings/0001448431-26-000011.md) | [1.3](/filings/0001448431-26-000016.md) |
| Shareholders' equity | $m | [116](/filings/0001213900-24-098319.md) | [127](/filings/0001448431-26-000005.md) | [123](/filings/0001448431-25-000020.md) | [121](/filings/0001448431-25-000020.md) | [114](/filings/0001448431-25-000020.md) | [117](/filings/0001448431-26-000016.md) | [116](/filings/0001448431-26-000016.md) | [119](/filings/0001448431-26-000016.md) | [122](/filings/0001448431-25-000020.md) | [128](/filings/0001448431-26-000016.md) | [130](/filings/0001448431-26-000016.md) | [131](/filings/0001448431-26-000016.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,473 d](/filings/0001213900-24-098319.md) | [(6,258) d](/filings/0001213900-25-025576.md) | [2,118](/filings/0001448431-25-000005.md) | [782 d](/filings/0001448431-25-000012.md) | [1,791 d](/filings/0001448431-25-000020.md) | [198 d](/filings/0001448431-26-000005.md) | [3,864](/filings/0001448431-26-000011.md) | [4,561 d](/filings/0001448431-26-000016.md) | [3,202 d](/filings/0001448431-25-000020.md) | [7,088 d](/filings/0001448431-26-000005.md) | [(467)](/filings/0001448431-26-000011.md) | [8,611 d](/filings/0001448431-26-000016.md) |
| Capital expenditure | $k | [33.4 d](/filings/0001213900-24-098319.md) | [5.0 d](/filings/0001213900-25-025576.md) | [32.0](/filings/0001448431-25-000005.md) | [45.0 d](/filings/0001448431-25-000012.md) | [18.0 d](/filings/0001448431-25-000020.md) | [17.0 d](/filings/0001448431-26-000005.md) | [27.0](/filings/0001448431-26-000011.md) | [10.0 d](/filings/0001448431-26-000016.md) | [10.0 d](/filings/0001448431-25-000020.md) | [11.0 d](/filings/0001448431-26-000005.md) | [21.0](/filings/0001448431-26-000011.md) | [35.0 d](/filings/0001448431-26-000016.md) |
| Share repurchases | $k | [0.0 d](/filings/0001213900-24-098319.md) | [0.0 d](/filings/0001213900-25-025576.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [18.0](/filings/0001213900-23-086885.md) | [17.1](/filings/0001213900-24-043749.md) | [17.0](/filings/0001213900-24-069700.md) | [16.6](/filings/0001213900-24-098319.md) | [18.2](/filings/0001448431-25-000005.md) | [18.3](/filings/0001448431-25-000012.md) | [18.3](/filings/0001448431-25-000020.md) | [18.5](/filings/0001448431-26-000011.md) | [19.0](/filings/0001448431-26-000016.md) | [19.5](/filings/0001448431-25-000020.md) | [18.8](/filings/0001448431-26-000011.md) | [18.8](/filings/0001448431-26-000016.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 18,835,951 at 2026-07-30, from the cover of the [10-Q filed 2026-08-13](/filings/0001448431-26-000016.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.